Brent Saunders, Bausch + Lomb CEO (Richard Drew/AP Images)
August 3, 2023 09:44 AM EDT
Deals

Bausch + Lomb CEO Brent Saun­ders search­es for small­er deals while 'di­gest­ing' $1.75B Xi­idra move

Andrew Dunn

Senior Biopharma Correspondent

In his sec­ond stint as CEO of Bausch + Lomb, Brent Saun­ders has stayed true to his deal­mak­ing rep­u­ta­tion.

Just a few months af­ter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times